港股異動 | 阿里健康高開3.16% 中期收入同比增近120%至41.17億元
格隆匯11月27日丨阿里健康(0241.HK)高開3.16%,報8.5港元,暫成交836萬港元,最新總市值1022億港元。阿里健康昨晚發佈截至9月30日止中期業績指,期內實現收入41.17億元(人民幣,下同),同比增長119.1%;毛利10.32億元,同比增長95%;期內虧損762.9萬元,同比大幅收窄91.5%;母公司擁有人應占虧損110.2萬元,同比大幅收窄98.7%;基本每股虧損0.01分。值得一提的是,阿里健康是阿里巴巴旗下醫療健康領域旗艦平台,阿里巴巴昨日登陸港交所,成為今年以來全球規模最大的新股發行,同時也是2011年以來香港融資規模最大的公開發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.